EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer

Recruiting now · Not applicable

Conditions studied: Cancer, Genetic Predisposition

In brief

5 to 10% of cancers are due to the presence of a constitutional genetic alteration. It can be inherited from parents (family form) or by accident, in the first moments of life after fertilization (sporadic form). In both cases, this genetic alteration is constitutional and transmissible to descendants. It is hereditary. When an hereditary early form is suspected, several well-known genes generally involved in genetic predispositions to cancer are found by a technique called " gene panel ". However, this analysis does not always identify the genetic predisposing factors for cancer. New techniques called "high-throughput exome sequencing (SHD-E)", allow more than the analysis of the the gene panel. These analysis allow to identify alterations in other genes that could contribute to the development of cancer. The objective of the Ex²trican study is to show, from patients with early cancer (sporadic or familial form), that this approach to exome sequencing can be effective to identify new genetic risk of cancer, when the first panel analysis of genes is negative.

Key facts

Study ID

NCT04141462

Run by

Centre Georges Francois Leclerc

People needed

613

Starts

2019-10-07

Expected to finish

2028-04-07

Last updated by the study team

2026-04-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Index case:
• Major or minor patient
• Histological or cytological evidence of malignant tumor diagnosis
• Patient with cancer before age 40 (or before age 30 for breast cancer).
• Absence of anomaly found on the oncogenetic panel tested in the predisposition concerned
• Patient affiliated to a social security scheme
• Signature of Informed Consent EXTRICAN
• Availability of a tumor sample if needed secondary functional studies
• Availability of both parents when the trio approach will be necessary in the population 1 (or validation of the indication in CPR in case of non-availability of both parents)
• Availability of affected relatives in population 2 (or validation of the indication in SPC in case of non-availability of the related person)
• Related:
• Major or minor patient
• Histological or cytological evidence of the diagnosis of malignant tumor if
• Patient affiliated to a social security scheme
• Signing informed consent EXTRICAN

You may not qualify if…

• Index and related case:
• Refusal of the patient participation
• Psychiatric illness and / or condition of the patient compromising the understanding of the information or the realization of the study
• Patient under guardianship, curatorship or safeguard of justice
• Pregnant woman

Where it is running

• Centre Georges-François Leclerc — Dijon, France (enrolling)
• CHRU Jean Minjoz — Besançon, France
• CHU de Dijon — Dijon, France
• CHU de Reims — Reims, France
• Polyclinique de Courlancy — Reims, France
• CH de Troyes — Troyes, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.